Nanoparticle-Mediated Drug Delivery for Treating Melanoma

Mundra, Vaibhav; Li, Wei; Mahato, Ram I.

doi:10.2217/nnm.15.111

Cited by 48 publications

(26 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strategies to deliver drugs to specific cell types are needed. Some approaches, such as transporter-mediated drug uptake 43 , bi-specific antibodies 44 , and nanoparticle-mediated delivery 45 , require further clinical evaluation.…”

Section: Integrating Knowledge and Keeping Metabolism In Mind When Dementioning

confidence: 99%

Emerging concepts of T cell metabolism as a target of immunotherapy

2016

View full text Add to dashboard Cite

Metabolism is the set of biochemical reactions that allows cells to acquire and utilize nutrients needed to sustain life. Accessing nutrients and meeting metabolic demands are necessary for cells to survive, proliferate, and to properly perform their intended functions. During an immune response leukocytes undergo major changes in growth and function that are tightly coupled to dynamic shifts in metabolic processes. Immunometabolism is an emerging field that investigates the interplay between immunological and metabolic processes. Interest in this field stems from the realization that incorrect metabolic remodeling underlies many aberrant immune responses, and that manipulating cellular metabolism can beneficially enhance or temper immunity.

show abstract

Section: Integrating Knowledge and Keeping Metabolism In Mind When Dementioning

confidence: 99%

Emerging concepts of T cell metabolism as a target of immunotherapy

2016

View full text Add to dashboard Cite

show abstract

“…It is plausible that there is more collagen in normal skin adjacent to DN than in that adjacent to MM because melanoma growth is not only associated with malignant growth of cancer cells, but also changes in its stroma microenvironment to support metastasis. 35 Paidi et al 36 discovered that the use of RS is feasible to detect changes in the stroma of the lung microenvironment in response to primary breast tumors. Sahu et al 37 found that early malignancyassociated changes in normal contralateral sites of oral cancer may lead to anatomical variability and cause misclassification between contralateral and tumor.…”

Section: Journal Of Biomedical Opticsmentioning

confidence: 99%

Raman biophysical markers in skin cancer diagnosis

et al. 2018

View full text Add to dashboard Cite

Raman spectroscopy (RS) has demonstrated great potential for in vivo cancer screening; however, the biophysical changes that occur for specific diagnoses remain unclear. We recently developed an inverse biophysical skin cancer model to address this issue. Here, we presented the first demonstration of in vivo melanoma and nonmelanoma skin cancer (NMSC) detection based on this model. We fit the model to our previous clinical dataset and extracted the concentration of eight Raman active components in 100 lesions in 65 patients diagnosed with malignant melanoma (MM), dysplastic nevi (DN), basal cell carcinoma, squamous cell carcinoma, and actinic keratosis. We then used logistic regression and leave-one-lesion-out cross validation to determine the diagnostically relevant model components. Our results showed that the biophysical model captures the diagnostic power of the previously used statistical classification model while also providing the skin's biophysical composition. In addition, collagen and triolein were the most relevant biomarkers to represent the spectral variances between MM and DN, and between NMSC and normal tissue. Our work demonstrates the ability of RS to reveal the biophysical basis for accurate diagnosis of different skin cancers, which may eventually lead to a reduction in the number of unnecessary excisional skin biopsies performed.

show abstract

“…The MSC-mediated oncolytic approach has been used also in experimental melanoma [123] and the potential of MSCs to deliver targeted agents in experimental melanoma has been previously reviewed [124]. An excellent survey of the use of NP-based therapeutics for melanoma treatment does not take in consideration MSCs or other cell-mediated delivery systems [125]. In the light of the strong evidence of magnetic resonance imaging of pulmonary metastases with magnetic NPs/ MSCs [126], tumor targeting with silica NPs/MSCs [127] and photothermal therapy with gold NPs/MSCs [128], it is our opinion that the theranostic use of MSC/NPs in melanoma is near to cross the boundary between the preclinical and the clinical phase.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma

Chillà

Margheri

Biagioni

et al. 2020

Cancers

View full text Add to dashboard Cite

Targeted and immune therapies have unquestionably improved the prognosis of melanoma patients. However the treatment of this neoplasm still requires approaches with a higher therapeutic index, in order to reduce shortcomings related to toxic effects and aspecific targeting. This means developing therapeutic tools derived with high affinity molecules for tumor components differentially expressed in melanoma cells with respect to their normal counterpart. Nanomedicine has sought to address this problem owing to the high modulability of nanoparticles. This approach exploits not only the enhanced permeability and retention effect typical of the tumor microenvironment (passive targeting), but also the use of specific “molecular antennas” that recognize some tumor-overexpressed molecules (active targeting). This line of research has given rise to the so-called “smart nanoparticles,” some of which have already passed the preclinical phase and are under clinical trials in melanoma patients. To further improve nanoparticles partition within tumors, for some years now a line of thought is exploiting the molecular systems that regulate the innate tumor-homing activity of platelets, granulocytes, monocytes/macrophages, stem cells, endothelial-colony-forming cells, and red blood cells loaded with nanoparticles. This new vision springs from the results obtained with some of these cells in regenerative medicine, an approach called “cell therapy.” This review takes into consideration the advantages of cell therapy as the only one capable of overcoming the limits of targeting imposed by the increased interstitial pressure of tumors.

show abstract

Nanoparticle-Mediated Drug Delivery for Treating Melanoma

Cited by 48 publications

References 195 publications

Emerging concepts of T cell metabolism as a target of immunotherapy

Emerging concepts of T cell metabolism as a target of immunotherapy

Raman biophysical markers in skin cancer diagnosis

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma

Contact Info

Product

Resources

About